Efavirenz-structure (Efavirenz Structure)
Not available.*
Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate Tablet, Film Coated
Product Images NDC 42385-929
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate (NDC 42385-929). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Laurus Labs Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Principal Display Panel (Container Label (30's count))
Each film-coated tablet contains Efavirenz USP 400mg, Lamivudine USP 300mg, and Tenofovir Disoproxil Fumarate USP 300mg (equivalent to Tenofovir Disoproxil 245mg). This medication is used for the treatment and management of human immunodeficiency virus (HIV) infections. The usual dosage for this medicine is specified in prescribing information which should be followed carefully. This package is child-resistant and should also be stored at 20° to 25°C (68° to 77°F) with controlled room temperature between 15° to 30°C (59° to 86°F) and should be kept safe from children's reach. Store the medication in its original container and keep it tightly closed with a Pharmacy label.*
Lamivudine-structure (Lamivudine Structure)
Tenofovir-structure (Tenofovir Structure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
